|
ARL5A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.4623968702665E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.98779947636308E-11 |
| Normal-vs-Stage2 |
1.959060E-03 |
| Normal-vs-Stage3 |
2.40160002995538E-10 |
| Normal-vs-Stage4 |
2.09288142372088E-12 |
| Stage1-vs-Stage2 |
5.659900E-02 |
| Stage1-vs-Stage3 |
2.201600E-01 |
| Stage1-vs-Stage4 |
2.017200E-03 |
| Stage2-vs-Stage3 |
1.791830E-02 |
| Stage2-vs-Stage4 |
3.387000E-04 |
| Stage3-vs-Stage4 |
5.835600E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.4535928844216E-14 |
| Normal-vs-AfricanAmerican |
3.87320000000413E-05 |
| Normal-vs-Asian |
3.63880003906303E-09 |
| Caucasian-vs-AfricanAmerican |
7.593200E-01 |
| Caucasian-vs-Asian |
7.962000E-01 |
| AfricanAmerican-vs-Asian |
6.775000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.22019949699848E-10 |
| Normal-vs-Female |
1.20110033030585E-10 |
| Male-vs-Female |
2.663600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.24990004404901E-09 |
| Normal-vs-Age(41-60Yrs) |
1.61850532975905E-11 |
| Normal-vs-Age(61-80Yrs) |
1.63509999984157E-07 |
| Normal-vs-Age(81-100Yrs) |
1.088970E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.240200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.414200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.048600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.742820E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.344400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.076000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.553530E-02 |
| Classical-VS-Follicular |
3.80589999959824E-07 |
| Classical-VS-Other |
7.770000E-01 |
| Classical-VS-Normal |
1.62481139653892E-12 |
| Tall-VS-Follicular |
5.93729998499271E-09 |
| Tall-VS-Other |
4.207400E-01 |
| Tall-VS-Normal |
1.81188397618826E-13 |
| Follicular-VS-Other |
7.492400E-02 |
| Follicular-VS-Normal |
8.341700E-02 |
| Other-VS-Normal |
8.956500E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.11940000047106E-07 |
| Normal-vs-N1 |
7.43849426498855E-14 |
| N0-vs-N1 |
1.422940E-04 |
|
|
